A Multicenter, Uncontrolled, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Perampanel as Substitute for Oral Tablet in Subjects With Partial Onset Seizures (Including Secondarily Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Perampanel (Primary) ; Antiepileptic drugs
- Indications Epilepsy; Partial epilepsies; Seizures; Tonic-clonic epilepsy
- Focus Adverse reactions
- Sponsors Eisai Inc
- 26 Nov 2019 Planned End Date changed from 20 Jan 2020 to 1 Apr 2020.
- 26 Nov 2019 Planned primary completion date changed from 20 Jan 2020 to 1 Jan 2020.
- 25 Nov 2019 Planned End Date changed from 1 Apr 2020 to 20 Jan 2020.